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Abstract
The objective of this study was to genetically engineer dendritic cells (DC) for biological activation and
evaluate their anti-tumor activity in a tumor-bearing mouse model. Mouse DC were incubated on the surface
of culture dishes which had been coated with the complexes of a cationized dextran and luciferase plasmid
DNA complexes plus a cell adhesion protein, Pronectin®, for gene transfection (reverse transfection). When
compared with the conventional transfection where DC were transfected in the medium containing the
complexes, the level of gene expression by the reverse method was significantly higher and the time period
of gene expression was prolonged. Following the reverse transfection of DC by a plasmid DNA of mouse
interleukin-12 (mIL-12) complexed with the cationized dextran, the mIL-12 protein was secreted at higher
amounts for a longer time period. When injected intratumorally into mice carrying a mass of B16 tumor
cells, the DC genetically activated showed significant anti-tumor activity.
© Koninklijke Brill NV, Leiden, 2010
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1. Introduction
Dendritic cells (DC) are antigen-presenting cells, which possess the capacity to
generate primary immune responses [1]. After the antigen uptake, DC process
these antigens into small peptides and move into secondary lymphoid organs to
present the antigenic peptides to lymphocytes for their immunological activation
[2–4]. Generally, DC are activated to biologically mature and subsequently obtain
immunological responsibility. The mature DC express high levels of cell-surface
major histocompatibility complexes, antigen complexes and co-stimulatory mole-
cules. Lymphocytes, such as naïve T-cells, helper CD4+ T-cells, cytolytic CD8+
T-cells, naïve B-cells, memory B-cells, natural killer cells and natural killer T-cells,
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are critical elements of immunological responses. DC play a central role in the nat-
ural immunization. Therefore, because of the function of DC, DC generated ex vivo
are highly expected to be promising cells, suitable for vaccination in cancer and
infectious diseases [5]. However, the immune response of DC is not strong enough
for vaccination in vigorous tumors. It is necessary for successful DC-based tumor
vaccination to activate the immunological function for anti-tumor response.
Interleukin-12 (IL-12) is a heterodimeric cytokine produced by DC, macro-
phages, polymorphonuclear leukocytes and keratinocytes [6]. The anti-tumor effect
of DC genetically modified with an IL-12 gene was examined in mouse tumor
models [7]. IL-12 enhances the anti-tumor effect of natural killer cells and cyto-
toxic T lymphocytes (CTL) activities, plays a key role in the induction of Th1-type
immune responses including interferon-gamma (IFN-γ ) production, and has
IFN-γ /IFN-inducible protein-10-dependent anti-angiogenic effects [8]. It has been
reported that following intratumoral injection, bone-marrow-derived DC, geneti-
cally modified with an IL-12 gene, showed enhanced uptake of tumor antigens at
the tumor site and moved into secondary lymphoid organs to induce an immune
response against the tumor [9]. Intratumoral injection of IL-12-engineered DC sup-
pressed the in vivo growth of tumors established and induced a strong anti-tumor
T-cell response [9]. However, in the studies reported, retrovirus or adenovirus vec-
tors have been used for genetic engineering of DC. This is because virus vectors
generally have high transfection efficiency. Adenoviruses and retroviruses have
several clinical limitations, such as mutagenesis, carcinogenesis, and induction of
immune responses. From the clinical viewpoint, it is desirable to develop an effi-
cient and safe non-viral carrier to genetically engineer DC for tumor vaccination.
Cationized polysaccharides of spermine-introduced dextran and pullulan have been
explored as a non-viral carrier for gene transfection [10–13]. Since polysaccha-
rides have reactive OH groups, the chemical modification is easy to give them
chemical, physical and biological functions. In addition, polysaccharides are com-
posed of different sugars which can be recognized by some sugar-recognizable
cell receptors. Complexation with the cationized polysaccharide allows plasmid
DNA to prepare a size-condensed structure with a positive charge, which efficiently
allows plasmid DNA to internalize into cells via receptor-mediated endocyto-
sis.
As the conventional procedure of gene transfection, a plasmid DNA is complexed
with the non-viral carrier, and then added to the culture medium of cells for gene
transfection. In this case, serum cannot be generally added to the culture medium,
although it is essential to give cells biological conditions good for culture. This is
because the plasmid DNA-carrier complexes often interact with serum components,
leading to the suppressed ability of gene transfection. To overcome the technical
problem, a new transfection system has been introduced [14]. Cells are cultured on
the surface of substrate which was coated with the plasmid DNA-cationized dextran
complexes and gene transfected in the presence of serum (reverse transfection). The
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transfection method enhanced the level of gene transfection to a significantly higher
extent compared with the conventional one.
The objective of this study is to investigate the gene transfection of DC for the ge-
netic engineering by the spermine–dextran of non-viral carrier and compared with
that of other transfection reagents commercially available. Moreover, gene transfec-
tion by the reverse transfection method with the spermine–dextran/plasmid DNA
complexes was carried out to enhance gene transfection efficiency [14]. DC ge-
netically engineered by the complexes of mouse interleukin 12 (mIL-12) plasmid
DNA and spermine–dextran were intratumorally injected to tumor-bearing mice
to evaluate the in vivo anti-tumor effect. We examined the IFN-γ production and
anti-tumor activity of spleen cells isolated from tumor-bearing mice injected with
engineered DC.
2. Materials and Methods
2.1. Materials
Dextran with a weight-average molecular weight of 74 000 and spermine were pur-
chased from Sigma (St. Louis, MO, USA). Pronectin® (Lot No. R1-7K002-A) was
kindly supplied by Sanyo Chemical Industries (Kyoto, Japan). Other chemicals
were obtained from Nacalai Tesque (Kyoto, Japan) and used without further pu-
rification.
2.2. Preparation of Cationized Dextran Derivatives
Spermine was introduced to the hydroxyl groups of dextran by a N,N′-carbonyl-
diimidazole (CDI) activation method [15]. Spermine (1870 mg) and CDI (225 mg)
were added to 50 ml dehydrated dimethyl sulfoxide (DMSO) containing 50 mg
dextran. Following agitation at 35◦C for 20 h, the reaction mixture was dialyzed
against ultra-pure double-distilled water (DDW) for 2 days with a dialysis mem-
brane (molecular mass cut-off 12–14 kDa, Viskase, Willowbrook, IL, USA). Then,
the solution was freeze-dried to obtain the spermine-introduced dextran (spermine–
dextran). When determined by conventional elemental analysis, the molar percent-
age of spermine introduced to the hydroxyl groups of dextran was 12.7 mol%.
2.3. Preparation of Plasmid DNA
The plasmid DNAs used were the pGL3 plasmid coding for a firefly luciferase gene
(Luciferase Reporter Vectors-pGL3, Promega, Madison, WI, USA), the pEGFP-N1
plasmid coding enhanced green fluorescent protein (Takara Bio, Shiga, Japan) and
the pGEG. mIL-12 plasmid coding for a bicistronic expression cassette for murine
IL-12 p35 and p40 genes [16], which was kindly supplied by Dr. Mazda, Kyoto Pre-
fectural University of Medicine (Kyoto, Japan). The pGEG is composed of CAG
(cytomegalovirus immediate-early enhancer-chicken beta-actin hybrid) promoter,
SV40 (Simian vacuolating virus 40) polyA additional signal, EBV oriP (Epstein–
Barr virus origin of plasmid replication), EBV EBNA1 (EBV-encoded nuclear
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antigen-1) gene and another CAG promoter. The plasmid DNA was propagated
in an Escherichia coli strain (DH5α) and purified by the Qiagen plasmid Mega kit
(Qiagen K.K., Tokyo, Japan) according to the manufacturers’ instructions. Both the
yield and purity of plasmid DNA were evaluated by UV spectroscopy (Ultrospec
2000, Pharmacia Biotech, Cambridge, UK). The absorbance ratio at wavelengths
of 260 to 280 nm for plasmid DNA solution was measured to be between 1.8
and 2.0.
2.4. Preparation of Polyion Complexes
Polyion complexes were prepared by mixing an aqueous solution of spermine–
dextran with that of plasmid DNA. Briefly, various amounts of spermine–dextran
were dissolved in 50 µl DDW and mixed with 50 µl phosphate-buffered saline (PBS,
10 mM, pH 7.4) solution containing 2.5 µg plasmid DNA, followed by leaving for
15 min at room temperature to obtain the polyion complexes of spermine–dextran
and plasmid DNA. The polyion complexes composition was calculated on the ba-
sis of the nitrogen number of spermine–dextran (N) per the phosphorus number of
plasmid DNA (P) and expressed as the N/P ratio. To complex the plasmid DNA with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), 50 µl Opti-MEM (Invitro-
gen) containing 5.0 µg Lipofectamine was mixed with 50 µl Opti-MEM containing
2.5 µg plasmid DNA, followed by leaving for 15 min at room temperature.
2.5. Preparation and Culture of DC
Mouse immature DC were obtained from bone marrow cells (BMC) through the
differentiation induction according to the conventional procedure previously re-
ported [17]. Briefly, mouse BMC were harvested from the femur and tibia of
4-week-old female ICR mice or 6-week-old female C57BL/6 mice (body weight
20 g, Shimizu Laboratory Supplies, Kyoto, Japan). Erythrocytes contaminated
in BMC were lysed with ammonium chloride solution and cells were seeded in
RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with penicillin
(100 U/ml, Sigma-Aldrich), streptomycin (100 µg/ml, Sigma-Aldrich), 10 vol%
heat-inactivated FCS (Hyclone Laboratories, Logan, UT, USA) and 200 U/ml
recombinant mouse-derived granulocyte macrophage colony-stimulating factor
(rmGM-CSF, 1 × 107 U/mg, Peprotech/Tebu, Frankfurt, Germany) on day 0. The
medium was changed every 2 days thereafter. The cells cultured for 9–14 days were
used for all experiments as mouse immature DC.
2.6. Conventional Gene Transfection
DC were seeded in each well of a 12-well multi-dish culture plate (Corning,
Corning, NY, USA) at a density of 2.5 × 105 cells/well and cultured in 1 ml of
RPMI-1640 medium with 10 vol% FCS and 50 U/ml rmGM-CSF for 24 h. Imme-
diately after the medium was exchanged by FCS and rmGM-CSF-free RPMI-1640
medium, 100 µl polyion complexes solution containing 2.5 µg plasmid DNA at dif-
ferent N/P ratios was added, and transfection culture was performed for 3 h. After
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the medium was changed to RPMI-1640 with 10 vol% FCS and rmGM-CSF, cells
were incubated further for 1, 4 and 7 days.
2.7. Reverse Gene Transfection
In vitro gene transfection by the reverse method was performed according to the
method described previously [14]. Briefly, succinic anhydride (90.1 mg) was added
to 20 ml of 100 mg/ml gelatin solution in DMSO, followed by agitation at room
temperature for 18 h to allow to introduce the carboxyl groups to the amino groups
of gelatin for anionization. When determined as the extent of amino groups de-
creased by the trinitrobenzene sulfonic acid method [18], the molar amount of
carboxylic groups introduced was 100 mol%. The aqueous solution of anionized
gelatin (100 µg/ml) and Pronectin (200 µg/ml) was placed into each well of 12-well
multi-dish culture plate and left at 37◦C for 1 h for coating. After PBS washing,
the well was coated with the polyion complexes solution containing 2.5 µg plasmid
DNA at an N/P ratio of 3. After 30 min incubation, the wells were washed with
PBS. Then, DC (2.5 × 105 cells/well) were seeded on the complexes-coated well,
followed by cell culture in the RPMI-1640 medium with 10 vol% FCS and 50 U/ml
rmGM-CSF for 2, 5 and 8 days.
2.8. Gene Expression Assay
To assay the level of luciferase expression, transfected cells were washed with PBS
once, lysed in 100 µl cell-culture lysis reagent (Promega, Madison, WI, UA), trans-
ferred into a micro reaction tube, and the cell debris was separated by centrifugation
(14×103 rpm, 20 min). Then, 100 µl luciferase assay reagent (Promega) was added
to 20 µl supernatant while the relative light unit (RLU) of the sample was deter-
mined by a luminometer (MicroLumatPlus LB 96V, Berthold, Tokyo, Japan). The
total protein of each well was determined using the bicinchonic acid (BCA) protein
assay kit (Pierce, Rockford, IL, USA) according to the manufacturers’ instructions.
The RLU was divided by the protein amount to normalize the influence of number
variance of cells on the luciferase activity. Each experimental group was carried out
three times independently.
To assay GFP expression efficacy, cells transfected were washed with PBS twice
and detached by trypsinization. After centrifugation (1000 rpm, 5 min), the cells
were resuspended and washed with PBS twice. Cells (1 × 104) were measured
by fluorescence activated cell sorter (FACS) Calibur with Cell Quest Pro Software
(Becton Dickinson Biosciences, San Jose, CA, USA). The percentage of positive
cells was calculated by setting the background population as 98% negative when
analyzing control cells [19].
After the reverse transfection culture with the spermine–dextran/mIL-12 plas-
mid DNA complexes for different time periods, the amount of mIL-12 produced
was measured by the mIL-12 enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems, Minneapolis, MN, USA) according to the manufacturers’ instruc-
tions.
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2.9. Evaluation of Plasmid DNA Internalization into Cells
Plasmid DNA was labeled with Cy5 using the Label IT® Cy5 Labeling Kit (Mirus
Bio, Madison, WI, USA). The Cy5-labeled plasmid DNA was complexed with
spermine–dextran. The cells were treated in cold acetate buffer containing 0.3 vol%
acetic acid, 0.085 M NaCl and 5.0 mM KCl for 1 min, washed with cold PBS
to remove the complexes bound to the cell surface. The cells were collected by
trypsinization, then 1 × 104 cells were measured by FACSCalibur flow cytome-
try. The percentage of Cy5-positive cells was calculated by setting the background
population as 98% negative when analyzing control cells.
2.10. Microscopic Observation of Intracellular Localization
After the conventional and reverse transfection of cultures for 1 day with the com-
plexes of Cy5-labeled plasmid DNA and the spermine–dextran, cells were washed
and fixed with 0.25 wt% glutaraldehyde solution in PBS, followed by staining nu-
cleus with Hoechst 33342 (Molecular Probes, Eugene, OR, USA). Imaging data
of cells were collected on an Olympus Fluoview FV300 confocal laser scanning
microscope (Olympus) and processed with Adobe Photoshop 6.0 software (Adobe
Systems, San Jose, CA, USA).
2.11. Cell Viability
Cytotoxicity after gene transfection was assayed using a cell counting kit (Nacalai
Tesque). The medium was changed to RPMI-1640 with FCS and rmGM-CSF,
10 µl 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tet-
razolium (WST-8) solution was added and the cells incubated for another 4 h. The
absorbance of samples was measured at 450 nm using a VERSAmax microplate
reader (Molecular Devices, Sunnyvale, CA, USA). The percentage cell viability
was expressed as 100% for non-transfected, control cells.
2.12. Evaluation of Anti-tumor Effect
B16 melanoma cells (1 × 105 cells/mouse) suspended in 200 µl of PBS were sub-
cutaneously inoculated into the right flank of C57BL/6 mice on day 0. DC were
genetically engineered by the reverse transfection with the complexes of spermine–
dextran/mIL-12 plasmid DNA as described previously. On day 9, when the tumor
size reached a approx. 0.10–0.05 cm3, tumor therapy with DC genetically en-
gineered was started. DC genetically engineered were taken off with a rubber
policeman, washed twice and resuspended in PBS. Then, 100 µl DC (1 × 106
cells) suspended in PBS was intratumorally injected. At different time periods after
intratumoral injection, the longest and widest diameter of tumor mass were mea-
sured with a caliper and the tumor volume was calculated by using the formula of
(length) × (width)2 × 1/2 [20]. As controls, PBS, non-transfected, original DC or
DC transfected with spermine–dextran/GFP–plasmid DNA complexes by the re-
verse method were injected.
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2.13. In Vitro Cytokine Release Assays
Splenocytes were obtained from the spleen harvested from tumor-bearing mice
7 days after intratumoral injection with PBS, original DC or those transfected with
the complexes of spermine–dextran and GFP or mIL-12 plasmid DNA by the re-
verse method. Briefly, the spleen taken was pressed through a sterile gauze, rinsed
twice. These cells (1×106 cells) were co-cultured in a 100-mm dish (Corning) with
mytomycin C (Sigma)-treated B16 cells (1 × 106 cells) in culture medium contain-
ing 25 U/ml recombinant mouse IL-2 (2.5 × 106 U/mg; Prospec, Rehovot, Israel)
for 6 days. Then, the culture medium was collected and the amount of interferon-γ
(IFN-γ ) was measured by mouse IFN-γ (R&D Systems) ELISA kits according to
the manufacturers’ instructions.
2.14. Measurement of Cytotoxic T-Lymphocyte (CTL) Activity
Splenocytes harvested as described above (1 × 106 cells) were stimulated in a
100-mm dish with mytomycin C-treated B16 cells (1×106 cells) in culture medium
containing 25 U/ml recombinant mouse IL-2 for 2 days. Then, the cells stimulated
were used as effectors for measurement of CTL activity. B16 (target) cells (5 × 104
cells each) were cultured in a 96-well multi-dish culture plate (Corning) for 24 h.
After washing twice, various number of effector cells were added to the plate. After
4 h co-culture, the supernatant (50 µl) was collected, and the lactate dehydrogenase
(LDH) activity was measured using the LDH-Cytotxic Test (Wako, Osaka, Japan).
The CTL activity was expressed as the number percentage of target cells injured by
splenocytes to those completely injured by adding 0.2 vol% Tween-20.
2.15. Evaluation of In Vivo Tumor Immunity
B16 cells (1 × 105 cells/mouse) suspended in 200 µl PBS were subcutaneously
inoculated into the both flanks of C57BL/6 mice on day 0. DC were genetically
engineered by reverse transfection with the complexes of spermine–dextran/mIL-
12 plasmid DNA as described previously. On day 9, 100 µl DC (1 × 106 cells)
suspended in PBS was injected into the tumor mass grown in the right flank of the
mice. At 29 days after intratumoral injection, each tumor volume in the both flanks
was calculated as described above. As controls, PBS, non-transfected, original DC
or those transfected with spermine–dextran/GFP–plasmid DNA complexes by the
reverse method was injected similarly.
2.16. Statistical Analysis
Numerical values were expressed as mean±SEM unless otherwise indicated. Com-
parisons of parameters between the 4 groups were made using one-way analysis of
variance, followed by the Newman–Keuls multiple comparison test. P < 0.05 was
considered to be significant.
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(a) (b)
Figure 1. (a) The level of luciferase expression in DC 1 day after transfection of luciferase plasmid
DNA complexed with the spermine–dextran at different N/P ratios by the conventional method. As
controls, free plasmid DNA and plasmid DNA complexes with Lipofectamine 2000 are used. The
amount of plasmid DNA used for transfection is 2.5 µg. (b) The level of luciferase expression in DC
1 day after transfection of luciferase plasmid DNA complexed with the spermine–dextran at a N/P
ratio of 3.0 by the conventional (filled column) and reverse methods (open columns). As control, free
plasmid DNA is used. The amount of plasmid used for transfection is 2.5 µg. ∗P < 0.05 versus the
expression level of DC transfected with free plasmid DNA. ∗∗P < 0.05 versus the expression level of
DC transfected with the spermine–dextran/plasmid DNA complexes by the conventional method.
3. Results
3.1. Gene Expression by Spermine–Dextran/Plasmid DNA Complexes
Figure 1 shows the level of luciferase expression for DC 1 day after transfection of
luciferase plasmid DNA complexed with the spermine–dextran at different N/P ra-
tios by the conventional and reverse method. In the conventional method, the level
of gene expression by the spermine–dextran/plasmid DNA complexes at a N/P ra-
tio of 3.0 was significantly higher than those of free plasmid DNA and the plasmid
DNA complexes of Lipofectamine 2000 or the spermine–dextrans at other N/P ra-
tios (Fig. 1a). On the other hand, the expression level by the reverse transfection
method was significantly higher than that of the conventional one (Fig. 1b).
Figure 2 shows the time-course of the percent internalized of GFP–plasmid DNA
and GFP expression for DC transfected with free plasmid DNA and spermine–
dextran/plasmid DNA complexes by the conventional and reverse methods. The
plasmid DNA in the free form could be hardly internalized while little gene ex-
pression was observed. For the plasmid DNA in the complexes form, there was
no difference in the time-course of plasmid DNA internalized into DC different
between the conventional and reverse methods, while the percentage of plasmid
DNA internalized was significantly higher for the reverse method than for the con-
ventional one (Fig. 2a). The level of GFP expressed by the conventional method
decreased with culture time, whereas it was retained at a high value for the reverse
method (Fig. 2b).
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(a) (b)
Figure 2. Time-course of percent GFP–plasmid DNA internalized (a) and GFP expression for DC (b)
transfected with free plasmid DNA and spermine–dextran/plasmid DNA complexes by the conven-
tional and reverse methods. The cells were cultured for 1 (black columns), 4 (open columns) and 7
days (gray columns). The amount of plasmid DNA used for transfection is 2.5 µg. The N/P ratio of
spermine–dextran/plasmid DNA complexes is 3.0. ∗P < 0.05 versus the percent GFP–plasmid DNA
internalized or GFP expression for DC transfected with free plasmid DNA at the corresponding time.
∗∗P < 0.05 versus the percent GFP–plasmid DNA internalized or GFP expression for DC transfected
with the spermine–dextran/plasmid DNA complexes by the conventional method at the corresponding
time.
Figure 3 shows the confocal laser microscopic images of DC 1 day after transfec-
tion with free plasmid DNA and spermine–dextran/plasmid DNA complexes by the
conventional and reverse methods. The plasmid DNA in the free form was hardly
internalized into DC. The number of internalized-plasmid DNA for the reverse
method tended to be larger than that of the conventional one.
3.2. Viability of DC Transfected by the Conventional and Reverse Methods
Figure 4 shows the viability of DC 1 day after transfection with free plasmid DNA,
plasmid DNA–Lipofectamine 2000 complexes and spermine–dextran/plasmid
DNA complexes by the conventional and reverse methods. The cell viability de-
creased significantly by the conventional transfection method with the spermine–
dextran and Lipofectamine 2000 complexes with plasmid DNA. In contrast, the
viability after the reverse transfection culture was similar to that of non-transfected,
original cells.
IL-12 expression of DC trasfected by spermine–dextran/mIL-12 plasmid DNA
complexes. Figure 5 shows the time-course of mIL-12 production of DC trans-
fected with PBS, complexes of spermine–dextran and GFP or mIL-12 plasmid
DNAs by the reverse method. The amount of mIL-12 produced by DC trans-
fected with the spermine–dextran/mIL-12 plasmid DNA complexes was signifi-
cantly higher than that of non-transfected, original DC until at least 14 days after
transfection. The amount of mIL-12 produced by DC transfected with spermine–




Figure 3. Confocal laser microscopic images of DC 1 day after transfection with free plasmid DNA (a)
and spermine–dextran/plasmid DNA complexes by the conventional (b) and reverse methods (c). The
plasmid DNA was labeled with Cy5. The amount of plasmid DNA used for transfection is 2.5 µg.
The N/P ratio of spermine–dextran/plasmid DNA complexes is 3.0. The red and blue points indicate
the plasmid DNA and cell nucleus, respectively. This figure is published in the online edition of this
journal, that can be accessed via http://www.brill.nl/jbs
dextran/GFP–plasmid DNA complexes increased with culture time and reached
plateau at 11 days.
3.3. In Vivo Anti-tumor Effect of DC Genetically Engineered with
Spermine–Dextran/mIL-12 Plasmid DNA by the Reverse Transfection Method
Figure 6 shows the time-course of tumor volume change after the intratumoral in-
jection of PBS, non-transfected, original DC and DC transfected with complexes
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Figure 4. Viability of DC 1 day after transfection with free plasmid DNA, plasmid
DNA–Lipofectamine 2000 complexes and spermine–dextran/plasmid DNA complexes by the con-
ventional and reverse methods. The amount of plasmid DNA used for transfection is 2.5 µg. The
N/P ratio of spermine–dextran/plasmid DNA complexes is 3.0. ∗P < 0.05 versus the viability of DC
without transfection.
Figure 5. Time-course of mIL-12 production in DC transfected with PBS (closed bars), complexes
of spermine–dextran and GFP (gray bars) or mIL-12 plasmid DNAs (open bars) by the reverse
method. The amount of plasmid DNA used for transfection is 2.5 µg. The N/P ratio of sper-
mine–dextran/plasmid DNA complexes is 3.0. ∗P < 0.05 versus the amount of mIL-12 produced
by DC transfected with PBS at the corresponding time. ∗∗P < 0.05 versus the amount of IL-12 pro-
duced of DC transfected with spermine–dextran/GFP–plasmid DNA complexes at the corresponding
time.
of spermine–dextran and GFP or mIL-12 plasmid DNAs by the reverse method.
The intratumoral injection of DC transfected with the spermine–dextran/mIL-12
plasmid DNA complexes by the reverse method tended to suppress the in vivo
growth of tumor cells even at the early time period and exhibited significantly higher
anti-tumor effect in vivo than that of PBS, original DC, and DC transfected with
spermine–dextran/GFP–plasmid DNA complexes.
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Figure 6. Time-course of tumor volume change after intratumoral injection of PBS ("),
non-transfected, original DC (Q) and DC transfected with complexes of spermine–dextran and GFP
(2) or mIL-12 plasmid DNAs (!) by the reverse method. ∗P < 0.05 versus the tumor volume of other
groups at the corresponding time.
3.4. IFN Production and CTL Activity of DC Genetically Engineered with
Spermine–Dextran/mIL-12 Plasmid DNA by the Reverse Transfection Method
Figure 7 shows the IFN-γ secretion and CTL activity by the splenocytes of tumor-
bearing mice 7 days after intratumoral injection of PBS, non-transfected, original
DC, and DC transfected with complexes of spermine–dextran and GFP or mIL-12
plasmid DNAs by the reverse transfection method. Intratumoral injection of DC ge-
netically engineered with the spermine–dextran/mIL-12 plasmid DNA complexes
by the reverse method enhanced IFN-γ production of splenocytes to a significantly
greater extent compared with that of original DC or those genetically engineered
with spermine–dextran/GFP–plasmid DNA complexes by the reverse transfection
method (Fig. 7a). For DC transfected with the spermine–dextran/mIL-12 plasmid
DNA complexes, as the effector/target ratio increased, the CTL activity of spleno-
cytes harvested became high to a significantly greater extent compared with that of
original DC or those genetically engineered with spermine–dextran/GFP–plasmid
DNA complexes by the reverse transfection method (Fig. 7b).
3.5. Evaluation of In Vivo Tumor Immunity
To confirm the induction of systemic and therapeutic immunity, the growth of con-
tralateral non-treated tumor, which is distant from the tumor mass injected with DC
genetically engineered by the spermine–dextran/mIL-12 plasmid DNA complexes,
was evaluated (Table 1). Intratumoral injection of DC genetically engineered sig-
nificantly suppressed the growth of the tumor mass, irrespective of the direct injec-
tion.
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(a) (b)
Figure 7. (a) IFN-γ secretion by splenocytes of tumor-bearing mice 7 days after intratumoral injection
of PBS, non-transfected, original DC (DC) and DC transfected with complexes of spermine–dextran
and GFP (DC–GFP) or mIL-12 plasmid DNAs (DC–IL-12) by the reverse method. ∗P < 0.05 versus
the amount of IFN-γ secreted for the PBS group. ∗∗P < 0.05 versus the amount of IFN-γ secreted
for the DC group. †P < 0.05 versus the amount of IFN-γ secreted for the DC–GFP group. (b) CTL
activity as a function of effector/target ratio. CTL activity was expressed as the percentage of B16
(target) cells injured by co-culture with splenocytes (effector) harvested from tumor-bearing mice 7
days after the intratumoral injection of PBS ("), non-transfected, original DC (Q) and DC transfected
with complexes of spermine–dextran and GFP (2) or mIL-12 plasmid DNAs (!) by the reverse
method. ∗P < 0.05 versus the percentage of B16 cells injured by other groups at the corresponding
effector/target ratio.
Table 1.
Tumor volume in both flanks of tumor-bearing mice with or
without intratumoral of genetically engineered DC
Tumor volume (cm3)
Injected Not injected
PBS 9.9 ± 1.4 9.6 ± 1.9
DC 8.0 ± 0.4 7.8 ± 0.9
DC–GFP 7.3 ± 0.0 8.5 ± 0.0
DC–IL-12 5.6 ± 0.9∗ 5.9 ± 0.1∗
Tumor volume was measured 29 days after inoculation.
∗P < 0.05 versus the tumor volume of other groups.
4. Discussion
The present study clearly demonstrated that DC genetically engineered by IL-12
plasmid DNA complexed with the spermine–dextran enhanced the anti-tumor effect
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through the immune surveillance potential. The in vivo growth of tumor cells was
significantly suppressed by injection of engineered DC (Fig. 6). The splenocytes
isolated from tumor-bearing mice following the injection of engineered DC showed
the IFN production and CTL activity (Fig. 7). The tumor growth suppression was
observed even for the tumor mass without the direct DC injection (Table 1).
To genetically engineer cells, it is necessary to develop the technology and
methodology of gene transfection. Viral vectors have been mainly used for this pur-
pose because of the high transfection efficiency. However, there are scientific and
ethical barriers to use the viral transfection for clinical applications. As one trial
to tackle this issue, various non-viral carriers have been investigated [21–24]. To
enhance the level of gene expression, in addition to the research and development
of gene carriers themselves, it is indispensable to improve the culture technology
and methodology of cells for gene transfection. It is highly expected that the cul-
ture conditions always affect the biological state of cells which strongly contribute
to the level of gene transfection.
In this study, spermine–dextran was used for gene transfection. Complexation
with the spermine–dextran of a non-viral vector enabled the plasmid DNA to
decrease the apparent size of spermine–dextran plasmid DNA complexes small
enough to allow their cellular internalization and to have a positive surface charge
which can interact with the cell surface of negative charge. Moreover, it has been
reported that many types of sugar-recognizable receptor are expressed on DC [25].
Taken together, it is highly possible that the spermine–dextran/plasmid DNA com-
plexes were internalized into the DC via receptor-mediated endocytosis. It is highly
conceivable that the features promoted the transfection of plasmid DNA for DC,
enhancing the level of gene expression.
Dextran is a water-soluble, naturally occurring polysaccharide with multiple hy-
droxyl groups applicable to chemical modification. It also has low immunogenicity
and a long history for the clinical use as a plasma expander [26]. The level of gene
expression of DC by the spermine–dextran/plasmid DNA complexes at a N/P ratio
of 3.0 was significantly higher than that by Lipofectamine 2000 of a commercially
available transfection reagent (Fig. 1a). It has been previously reported that the
N/P ratio affects not only the physicochemical properties of the complexes, but
also the gene transfection efficiency [11, 13]. At low N/P ratios, the complexes
formed are unstable and have too large molecular size to be internalized into cells,
resulting in low gene transfection efficiency. On the other hand, at high N/P ra-
tios, the complexes are too stable to dissociate and have high cytotoxicity due to
the excessive amount of cationic spermine–dextran, resulting in low gene transfec-
tion efficiency. Therefore, it is possible that the complexes at a N/P ratio of 3.0
have a condition suitable for gene transfection of DC. Considering these points, the
spermine–dextran is a promising non-viral vector to enhance the gene expression
of DC through the enhanced receptor-mediated endocytosis.
We have demonstrated that the reverse transfection method gives cells good cul-
ture conditions, resulting in enhanced and prolonged gene expression with less
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cytotoxicity [14]. The efficacy of reverse transfection in gene expression was also
confirmed in this study for the luciferase (Fig. 1b), GFP (Fig. 2) and mIL-12 plas-
mid DNAs (Fig. 5). The higher efficiency of gene transfection can be explained in
terms of the unique feature of the reverse method. DC are always cultured on com-
plexes of plasmid DNA and spermine–dextran of a non-viral carrier. It is likely that
the localization of plasmid DNA close to cells enhances the possibility of cellular
internalization of plasmid DNA, resulting in increased efficiency of gene transfec-
tion. In addition, the transfection culture can be performed in the presence of serum,
which is a condition better for cell culture. It is apparent from Fig. 3 that the plasmid
DNA was localized in the nucleus of cells at higher amounts. This may be also due
to the efficient and continuous supply of plasmid DNA to cells (Fig. 2). Different
behaviors between the time-course of percent internalized of GFP–plasmid DNA
(Fig. 2a) and that of GFP expression (Fig. 2b) for DC transfected with spermine–
dextran/plasmid DNA complexes by the reverse method were observed. It will take
some time to express protein after gene transfection. Thus, the time between the
plasmid DNA internalization and gene expression would be observed. When cells
internalize the complexes too much, it is conceivable that their capacity to take up
decreases. Therefore, the percent internalized would decrease at day 7.
Although less cytotoxicity was observed (Fig. 4), transfection of the spermine–
dextran/GFP–plasmid DNA complexes affected not only the amount of mIL-12
produced in DC (Fig. 5), but also that of IFN-γ secreted by splenocytes (Fig. 7a). It
is well known that DC themselves tend to produce IL-12 by various stimuli [27, 28].
Therefore, it is possible that only the stimulus of plasmid DNA transfection allows
DC to produce IL-12. Enhancement of IFN production by spermine–dextran/GFP–
plasmid DNA complexes may be explained in terms of interaction of DC and IL-12.
It has been reported that IFN production from DC is influenced by IL-12 action
[29, 30]. The roles of DC and T-cells in the tumor immunity are as follows [1]. DC
phagocytoses a tumor antigen in the tumor tissue. Then, DC process these antigens
into small peptides and move into the lymphoid organs, such as the spleen. During
these steps, DC are biologically matured and obtain immunological responsibility,
which express high levels of cell-surface major histocompatibility complexes anti-
gen complexes and co-stimulatory molecules. Receptors of helper CD4+ T-cells
(Th0) in the lymphoid organs interact with the MHC class II of the DC, followed
by the differentiation into the T-helper 1 (Th1) or 2 (Th2) cells and IFN produc-
tion. On the other hand, it has been reported that IL-12 promotes the differentiation
of Th0 cells into Th1 cells [31–33], enhances CTL activity by CD8+ T-cells [34],
and infiltration of T-cells into the tumor tissue [35]. In the present study, the in-
tratumoral injection of DC genetically engineered with spermine–dextran/mIL-12
plasmid DNA complexes by the reverse method suppressed tumor growth (Fig. 6)
and induced a strong anti-tumor T-cell response (Fig. 7). These results suggest that
mIL-12 over-expression at the tumor site or, alternatively, in the secondary lym-
phoid sites could be important for the anti-tumor response. Chemokine production
induced by mIL-12/IFN-γ elaboration at the tumor site would be responsible for
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these effects, at least in part, through enhanced recruitment of cytolytic effector
cells into tumors as well as possibly anti-angiogenic effects. It is apparent from
Fig. 6 that the tumor growth was gradually suppressed by the intratumoral injection
of DC genetically engineered with spermine–dextran/mIL-12 plasmid DNA com-
plexes by the reverse transfection method (Fig. 6). It may be due to that there are
many steps in tumor immunity as described above; consequently, it takes some time
to express the tumor suppression. Systemic immune responses, as demonstrated by
IFN-γ production and CTL activity (Fig. 7), were also significantly higher and
tumor specific when injected DC genetically engineered. These findings well cor-
respond to those of research where DC genetically engineered with IL-12 gene by
retrovirus were intratumorally injected [9]. These results indicate that high cyto-
toxic activity in association with a Th1-type response could indeed contribute to
the profound in vivo anti-tumor effects. Experiments involving a subsequent re-
challenge with additional tumors (Table 1) further confirmed systemic anti-tumor
immunity after treatment intratumoral injection of DC with genetically engineered.
In conclusion, we developed a novel efficient gene delivery into DC with
spermine–dextran of a non-viral vector. Intratumoral injection of DC genetically
engineered is therapeutically feasible, mediates an effective anti-tumor response,
and is capable of inducing substantial systemic anti-tumor immunity.
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